Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics, Inc. director Edris Badreddin received new equity-based compensation. On June 5, 2026, he was granted stock options for 8,188 shares of common stock at an exercise price of $35.59 per share, expiring on June 5, 2036. He also received 5,619 Restricted Stock Units (RSUs). According to the terms, 100% of both the options and RSUs will vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of stockholders. These are compensation grants, not open‑market purchases or sales.
Edgewise Therapeutics, Inc. director Martin Christopher Nathan reported receiving a grant of stock options on Common Stock. The award covers 16,377 stock options with an exercise price of $35.59 per share, giving him the right to buy the same number of common shares in the future.
According to the grant terms, all of these options vest 100% on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. The options expire on June 5, 2036, and he held 16,377 derivative securities from this grant following the transaction.
Edgewise Therapeutics director Jonathan C. Fox received a grant of stock options, giving him rights to acquire 16,377 shares of common stock. The options have an exercise price of $35.59 per share and fully vest on the earlier of June 5, 2027 or the business day before the 2027 annual stockholder meeting. Following this grant, he holds 16,377 stock options directly as reported in this filing. This is a compensation-related award rather than an open-market purchase or sale.
Edgewise Therapeutics, Inc. reported results of its Annual Meeting of stockholders held on June 4, 2026. Stockholders elected three Class II directors — Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. — to serve until the 2029 annual meeting, with each to continue until a successor is elected and qualified.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 99,637,228 votes for, 1,123 against, and 578,031 abstaining. In addition, stockholders approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 87,055,111 votes for, 3,491,326 against, and 577,257 abstaining.
Edgewise Therapeutics entered a definitive agreement for Servier to acquire sevasemten and its muscular dystrophy business for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for potential total consideration of $2.65 billion. The deal is subject to customary conditions, including Hart-Scott-Rodino antitrust clearance, and is expected to close in Q3 2026. Edgewise states the upfront proceeds, together with existing cash, are expected to fully fund EDG-7500 through potential approval and support expansion of its cardiovascular pipeline, which includes EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. The company plans to report 12-week CIRRUS-HCM Part D data in Q2 2026 and target Phase 3 initiation of EDG-7500 in Q4 2026.
Edgewise Therapeutics entered a definitive agreement for Servier to acquire sevasemten and its muscular dystrophy business for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for potential total consideration of $2.65 billion. The deal is subject to customary conditions, including Hart-Scott-Rodino antitrust clearance, and is expected to close in Q3 2026. Edgewise states the upfront proceeds, together with existing cash, are expected to fully fund EDG-7500 through potential approval and support expansion of its cardiovascular pipeline, which includes EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. The company plans to report 12-week CIRRUS-HCM Part D data in Q2 2026 and target Phase 3 initiation of EDG-7500 in Q4 2026.
Edgewise Therapeutics, Inc. disclosure: Janus Henderson Group plc reported beneficial ownership of 5,915,556 shares of common stock, representing 5.5% of the class as of 03/31/2026. The filing states the Asset Managers exercise shared voting and dispositive power over these shares on behalf of Managed Portfolios. The Asset Managers disclaim rights to receive dividends or sale proceeds; the Managed Portfolios themselves have the rights to dividends and proceeds and, according to the filing, no single Managed Portfolio owns more than 5%.
Edgewise Therapeutics reported first quarter 2026 results highlighted by continued investment in its muscle and cardiovascular pipeline and a larger loss. Net loss was $49.0 million, or $0.46 per share, compared with $40.8 million, or $0.43 per share, a year earlier.
Research and development expenses rose to $42.7 million from $36.8 million, and general and administrative expenses increased to $11.5 million from $9.2 million. The company ended March 31, 2026 with $499.6 million in cash, cash equivalents and marketable securities. Edgewise also reported positive long-term sevasemten data in Becker muscular dystrophy and reiterated key upcoming readouts, including GRAND CANYON pivotal data in Becker in the fourth quarter of 2026 and 12-week CIRRUS-HCM data in hypertrophic cardiomyopathy in the second quarter of 2026.
Edgewise Therapeutics reported a net loss of $49.0 million for the three months ended March 31, 2026, as it continued investing heavily in late-stage clinical programs for severe muscle and cardiac diseases. Research and development expenses rose to $42.7 million, with spending focused on sevasemten, EDG-7500, EDG-15400 and discovery work.
The company held $499.6 million in cash, cash equivalents and marketable securities as of March 31, 2026 and believes this will fund operations for at least 12 months. Total assets were $518.5 million and stockholders’ equity was $493.2 million, reflecting a development-stage profile with an accumulated deficit of $595.4 million and no product revenue yet.
Insider sale notice: A Form 144 reports a proposed sale of 50,000 shares of Common Stock related to an exercise of stock options, dated 05/05/2026, with cash proceeds specified. The filing also lists recent Rule 10b5-1 sales totaling 71,588 shares across March–May 2026.
Edgewise Therapeutics, Inc. CMO Joanne M. Donovan reported an option exercise and related stock sales. On May 5, 2026, she exercised stock options to acquire 50,000 shares of common stock at $7.08 per share, then sold 50,000 shares at an average price of $38.568.
On May 4, 2026, she also sold 5,230 shares at an average price of $31.2931. The filing notes both sales were made in multiple transactions within disclosed price ranges and were effected under a Rule 10b5-1 Plan adopted on December 26, 2025. Following these transactions, she directly holds 4,367 shares of Edgewise Therapeutics common stock.